Your browser doesn't support javascript.
Off-label Uses of Selective Serotonin Reuptake Inhibitors (SSRIs).
Jannini, Tommaso B; Lorenzo, Giorgio D; Bianciardi, Emanuela; Niolu, Cinzia; Toscano, Massimiliano; Ciocca, Giacomo; Jannini, Emmanuele A; Siracusano, Alberto.
  • Jannini TB; Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
  • Lorenzo GD; Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
  • Bianciardi E; IRCCS-Fondazione Santa Lucia, Rome, Italy.
  • Niolu C; Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
  • Toscano M; Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
  • Ciocca G; Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy.
  • Jannini EA; Department of Neurology, Fatebenefratelli Hospital, Isola Tiberina, Rome, Italy.
  • Siracusano A; Department of Dynamic and Clinical Psychology, and Health Studies, Sapienza University of Rome, Rome, Italy.
Curr Neuropharmacol ; 20(4): 693-712, 2022.
Article in English | MEDLINE | ID: covidwho-2231392
ABSTRACT
Psychiatric drugs have primacy for off-label prescribing. Among those, selective serotonin reuptake inhibitors (SSRIs) are highly versatile and, therefore, widely prescribed. Moreover, they are commonly considered as having a better safety profile compared to other antidepressants. Thus, when it comes to off-label prescribing, SSRIs rank among the top positions. In this review, we present the state of the art of off-label applications of selective serotonin reuptake inhibitors, ranging from migraine prophylaxis to SARS-CoV-2 antiviral properties. Research on SSRIs provided significant evidence in the treatment of premature ejaculation, both with the on-label dapoxetine 30 mg and the off-label paroxetine 20 mg. However, other than a serotoninergic syndrome, serious conditions like increased bleeding rates, hyponatremia, hepatoxicity, and post-SSRIs sexual dysfunctions, are consistently more prominent when using such compounds. These insidious side effects might be frequently underestimated during common clinical practice, especially by nonpsychiatrists. Thus, some points must be addressed when using SSRIs. Among these, a psychiatric evaluation before every administration that falls outside the regulatory agencies-approved guidelines has to be considered mandatory. For these reasons, we aim with the present article to identify the risks of inappropriate uses and to advocate the need to actively boost research encouraging future clinical trials on this topic.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Selective Serotonin Reuptake Inhibitors / COVID-19 Drug Treatment Type of study: Experimental Studies / Prognostic study Limits: Humans / Male Language: English Journal: Curr Neuropharmacol Year: 2022 Document Type: Article Affiliation country: 1570159x19666210517150418

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Selective Serotonin Reuptake Inhibitors / COVID-19 Drug Treatment Type of study: Experimental Studies / Prognostic study Limits: Humans / Male Language: English Journal: Curr Neuropharmacol Year: 2022 Document Type: Article Affiliation country: 1570159x19666210517150418